Stimulate the eye’s natural healing response
Clinically proven to delay AMD
The Laser Intervention in Early AMD (LEAD) clinical trial, a large randomized, controlled clinical trial, has demonstrated the potential for 2RT® to significantly reduce the rate of disease progression in a specific group of intermediate AMD patients.1 Specifically, post hoc analyses showed that in patients who did not have coexistent reticular pseudodrusen (RPD), a fatty deposit that is associated with later stages of AMD (76% of patients enrolled), treatment with 2RT® resulted in a clinically meaningful 77% reduction in the rate of disease progression.Access the LEAD Trial Results
Access the LEAD Trial Design/Baseline Characteristics (abstract)
1. Guymer RH, Wu Z, Hodgson LAB, et al. Sub-Threshold Nanosecond Laser Intervention in Age-Related Macular Degeneration: The LEAD Randomized Controlled Clinical Trial. Ophthalmology. 2018.
Positive outcomes for retinal rejuvenation
With studies demonstrating the potential for Retinal Rejuvenation Therapy to positively influence the early stages of Age-Related Macular Degeneration (AMD) and Clinically Significant Macular Edema (CSME), 2RT's non-thermal laser therapy stimulates a natural, biological healing response in the eye.
Ellex 2RT® utilizes an ultra-short nanosecond laser pulse to target the compromised retinal pigment epithelium (RPE). A unique, proprietary pixelated beam profile ensures the selective targeting of nano-sized targets within the cellular structure of ageing RPE cells. With Nanopix Technology™ you can induce the orderly replacement of ageing RPE cells – without causing collateral damage to the overlying photoreceptor rods and cones of the retina.
The clinical application of Ellex’s Nanopix Technology™ is unique to Ellex 2RT® and cannot be extrapolated to other forms of retinal laser treatment, including subthreshold laser treatment.
AMD – earlier intervention
Ellex 2RT® offers the potential to intervene earlier in the disease process to improve retinal function and thereby slow the degenerative processes associated with AMD in its early stages. Clinical and scientific studies show that 2RT® can induce a mononuclear cell response in the early intervention of AMD, including the stimulation of microglia.1,2
CSME – thermal damage avoided
Unlike conventional retinal photocoagulation, which can cause permanent damage to the eye's sensitive structures, 2RT® uses 500 times less energy than retinal photocoagulation and eliminates the incidence of heat damage to the retina and surrounding cells in the effective treatment of Clinically Significant Macular Edema (CSME).3
1. Jobling et al., “Nanosecond Laser Therapy Reverses Pathologic and Molecular Changes in Age-Related Macular Degeneration without Retinal Damage,” The FASEB Journal 29, no. 2 (February 1, 2015): 696–710, doi:10.1096/fj.14-262444.
2. Guymer, R.H., et al., Nanosecond-laser application in intermediate AMD – 12-month results of fundus appearance and macular function. Clin Experiment Ophthalmol. 2013 Oct 3. doi: 10.1111/ceo.12247.
3. Casson RJ. Et al., “Pilot randomized trial of a nanopulse retinal laser versus conventional photocoagulation for the treatment of diabetic macular oedema”, Clin Experiment Ophthalmol. 2012 Aug;40(6):604-10